Line” rating to Kimberly-Clark Corporation (KMB), suggesting that while the stock is fairly valued at its current price of $100.64, there appears to be upside potential toward the $120 price target.

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Fintel reports that on November 4, 2025, Evercore ISI Group downgraded their outlook for Kimberly-Clark (NasdaqGS:KMB) from ...